Cargando…

Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil

BACKGROUND: The city of Manaus, north Brazil, was stricken by a second epidemic wave of SARS-CoV-2 despite high seroprevalence estimates, coinciding with the emergence of the Gamma (P.1) variant. Reinfections were postulated as a partial explanation for the second surge. However, accurate calculatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Prete, Carlos A., Buss, Lewis F., Buccheri, Renata, Abrahim, Claudia M. M., Salomon, Tassila, Crispim, Myuki A. E., Oikawa, Marcio K., Grebe, Eduard, da Costa, Allyson G., Fraiji, Nelson A., do P. S. S. Carvalho, Maria, Whittaker, Charles, Alexander, Neal, Faria, Nuno R., Dye, Christopher, Nascimento, Vítor H., Busch, Michael P., Sabino, Ester Cerdeira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817641/
https://www.ncbi.nlm.nih.gov/pubmed/35123418
http://dx.doi.org/10.1186/s12879-022-07094-y
_version_ 1784645690111033344
author Prete, Carlos A.
Buss, Lewis F.
Buccheri, Renata
Abrahim, Claudia M. M.
Salomon, Tassila
Crispim, Myuki A. E.
Oikawa, Marcio K.
Grebe, Eduard
da Costa, Allyson G.
Fraiji, Nelson A.
do P. S. S. Carvalho, Maria
Whittaker, Charles
Alexander, Neal
Faria, Nuno R.
Dye, Christopher
Nascimento, Vítor H.
Busch, Michael P.
Sabino, Ester Cerdeira
author_facet Prete, Carlos A.
Buss, Lewis F.
Buccheri, Renata
Abrahim, Claudia M. M.
Salomon, Tassila
Crispim, Myuki A. E.
Oikawa, Marcio K.
Grebe, Eduard
da Costa, Allyson G.
Fraiji, Nelson A.
do P. S. S. Carvalho, Maria
Whittaker, Charles
Alexander, Neal
Faria, Nuno R.
Dye, Christopher
Nascimento, Vítor H.
Busch, Michael P.
Sabino, Ester Cerdeira
author_sort Prete, Carlos A.
collection PubMed
description BACKGROUND: The city of Manaus, north Brazil, was stricken by a second epidemic wave of SARS-CoV-2 despite high seroprevalence estimates, coinciding with the emergence of the Gamma (P.1) variant. Reinfections were postulated as a partial explanation for the second surge. However, accurate calculation of reinfection rates is difficult when stringent criteria as two time-separated RT-PCR tests and/or genome sequencing are required. To estimate the proportion of reinfections caused by Gamma during the second wave in Manaus and the protection conferred by previous infection, we identified anti-SARS-CoV-2 antibody boosting in repeat blood donors as a mean to infer reinfection. METHODS: We tested serial blood samples from unvaccinated repeat blood donors in Manaus for the presence of anti-SARS-CoV-2 IgG antibodies using two assays that display waning in early convalescence, enabling the detection of reinfection-induced boosting. Donors were required to have three or more donations, being at least one during each epidemic wave. We propose a strict serological definition of reinfection (reactivity boosting following waning like a V-shaped curve in both assays or three spaced boostings), probable (two separate boosting events) and possible (reinfection detected by only one assay) reinfections. The serial samples were used to divide donors into six groups defined based on the inferred sequence of infection and reinfection with non-Gamma and Gamma variants. RESULTS: From 3655 repeat blood donors, 238 met all inclusion criteria, and 223 had enough residual sample volume to perform both serological assays. We found 13.6% (95% CI 7.0–24.5%) of all presumed Gamma infections that were observed in 2021 were reinfections. If we also include cases of probable or possible reinfections, these percentages increase respectively to 22.7% (95% CI 14.3–34.2%) and 39.3% (95% CI 29.5–50.0%). Previous infection conferred a protection against reinfection of 85.3% (95% CI 71.3–92.7%), decreasing to respectively 72.5% (95% CI 54.7–83.6%) and 39.5% (95% CI 14.1–57.8%) if probable and possible reinfections are included. CONCLUSIONS: Reinfection by Gamma is common and may play a significant role in epidemics where Gamma is prevalent, highlighting the continued threat variants of concern pose even to settings previously hit by substantial epidemics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07094-y.
format Online
Article
Text
id pubmed-8817641
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88176412022-02-07 Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil Prete, Carlos A. Buss, Lewis F. Buccheri, Renata Abrahim, Claudia M. M. Salomon, Tassila Crispim, Myuki A. E. Oikawa, Marcio K. Grebe, Eduard da Costa, Allyson G. Fraiji, Nelson A. do P. S. S. Carvalho, Maria Whittaker, Charles Alexander, Neal Faria, Nuno R. Dye, Christopher Nascimento, Vítor H. Busch, Michael P. Sabino, Ester Cerdeira BMC Infect Dis Research BACKGROUND: The city of Manaus, north Brazil, was stricken by a second epidemic wave of SARS-CoV-2 despite high seroprevalence estimates, coinciding with the emergence of the Gamma (P.1) variant. Reinfections were postulated as a partial explanation for the second surge. However, accurate calculation of reinfection rates is difficult when stringent criteria as two time-separated RT-PCR tests and/or genome sequencing are required. To estimate the proportion of reinfections caused by Gamma during the second wave in Manaus and the protection conferred by previous infection, we identified anti-SARS-CoV-2 antibody boosting in repeat blood donors as a mean to infer reinfection. METHODS: We tested serial blood samples from unvaccinated repeat blood donors in Manaus for the presence of anti-SARS-CoV-2 IgG antibodies using two assays that display waning in early convalescence, enabling the detection of reinfection-induced boosting. Donors were required to have three or more donations, being at least one during each epidemic wave. We propose a strict serological definition of reinfection (reactivity boosting following waning like a V-shaped curve in both assays or three spaced boostings), probable (two separate boosting events) and possible (reinfection detected by only one assay) reinfections. The serial samples were used to divide donors into six groups defined based on the inferred sequence of infection and reinfection with non-Gamma and Gamma variants. RESULTS: From 3655 repeat blood donors, 238 met all inclusion criteria, and 223 had enough residual sample volume to perform both serological assays. We found 13.6% (95% CI 7.0–24.5%) of all presumed Gamma infections that were observed in 2021 were reinfections. If we also include cases of probable or possible reinfections, these percentages increase respectively to 22.7% (95% CI 14.3–34.2%) and 39.3% (95% CI 29.5–50.0%). Previous infection conferred a protection against reinfection of 85.3% (95% CI 71.3–92.7%), decreasing to respectively 72.5% (95% CI 54.7–83.6%) and 39.5% (95% CI 14.1–57.8%) if probable and possible reinfections are included. CONCLUSIONS: Reinfection by Gamma is common and may play a significant role in epidemics where Gamma is prevalent, highlighting the continued threat variants of concern pose even to settings previously hit by substantial epidemics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07094-y. BioMed Central 2022-02-05 /pmc/articles/PMC8817641/ /pubmed/35123418 http://dx.doi.org/10.1186/s12879-022-07094-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Prete, Carlos A.
Buss, Lewis F.
Buccheri, Renata
Abrahim, Claudia M. M.
Salomon, Tassila
Crispim, Myuki A. E.
Oikawa, Marcio K.
Grebe, Eduard
da Costa, Allyson G.
Fraiji, Nelson A.
do P. S. S. Carvalho, Maria
Whittaker, Charles
Alexander, Neal
Faria, Nuno R.
Dye, Christopher
Nascimento, Vítor H.
Busch, Michael P.
Sabino, Ester Cerdeira
Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title_full Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title_fullStr Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title_full_unstemmed Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title_short Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
title_sort reinfection by the sars-cov-2 gamma variant in blood donors in manaus, brazil
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817641/
https://www.ncbi.nlm.nih.gov/pubmed/35123418
http://dx.doi.org/10.1186/s12879-022-07094-y
work_keys_str_mv AT pretecarlosa reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT busslewisf reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT buccherirenata reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT abrahimclaudiamm reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT salomontassila reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT crispimmyukiae reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT oikawamarciok reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT grebeeduard reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT dacostaallysong reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT fraijinelsona reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT dopsscarvalhomaria reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT whittakercharles reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT alexanderneal reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT farianunor reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT dyechristopher reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT nascimentovitorh reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT buschmichaelp reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil
AT sabinoestercerdeira reinfectionbythesarscov2gammavariantinblooddonorsinmanausbrazil